One Stop High-End Cosmetic OEM/ODM Tailored Technology and Aesthetics Merge to Rejuvenate Brands
Full-chain Independent R&D
BONTAC has independently developed a directed evolution platform, creating enzymes that do not exist in nature from scratch. With a current enzyme library of over 2000 varieties, the company utilizes directed evolution for genetic mutation and recombination. Through high-throughput AI screening, they repeatedly select superior enzyme varieties, forming a rich proprietary enzyme library. Compared to non-biological catalysts, these enzymes have extremely high catalytic efficiency, which is 100 to 1000 times more than that of conventional catalysts.
Synthetic route design
The classical retrosynthetic analysis in chemical synthesis is introduced into biosynthesis.
Directed evolutionary screening of enzymes
The target enzyme is subjected to the directed evolution with irrational，semi-rational or rational design, followed by the screening of high-through put mutation library to construct the standard target enzyme library.
Construction of enzyme strains
The selection of expression vectors and the construction of target strains are completed by the combined screening of components such as vector resistance，promoter，tag and expression host.
Expression of enzymes
The enzyme expression process is optimized by medium formulation, inducer and process control.
Optimization of catalytic process
Catalytic process parameters are optimized for better catalytic efficiency, higher yield and better product quality.
Rich enzyme libraries by independent research and development
Over 2000 enzyme varieties, with extremely high catalytic efficiency compared to non-biological catalysts, more than 100 times that of conventional catalysts.
The directed development of multi-enzyme cascades by
Developing an optimized process system for the preparation of coenzyme crude products through a one-step multi-enzyme cooperative catalysis reaction (i.e., multi-enzyme one-pot reaction).
High purity, easy to absorb, safer
Purification technology with low cost and high yield. The process of medium pressure column purification was abandoned, and the problem of hard decolorization of NAD and NMN products caused by enzyme catalysis was solved.
Prod-R&D Integration
R&D Center
Release U Health Product Ltd is located in New York City, with a company investment exceeding tens of millions of US dollars. It boasts facilities spanning tens of thousands of square meters that comply with Good Manufacturing Practice (GMP) standards, supporting large-scale production of biosynthetic fermentation ingredients, medicinal extracts, as well as finished products such as soft candies, liquid bars, and tablets.
Its parent company has received support from major investors including Nestlé of Switzerland and Plug and Play. Through collaborations with various universities, the company has established a research and development platform encompassing cell engineering, pilot-scale testing, 30-ton fermentation, and full purification systems, backed by a robust portfolio of patents and intellectual property rights in publications.
